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Abstract 
Objective: To evaluate the Annualized Relapse Rate (ARR) during washout and 
Alemtuzumab treatment in a real-life setting. 
Background: The effect of washout duration from previous Disease Modifying 
Treatment (DMT) before Alemtuzumab start is unknown. No data are currently 
available on the effect of Alemtuzumab when it is used after Fingolimod (FTY) or 
Natalizumab (NAT). 
Design/Methods: Patients who started alemtuzumab were included in this 
retrospective multicenter study. Previous therapy, washout duration and relapse 
occurrence were retrospectively assessed. Relapse rate in each epoch was analyzed 
with a negative binomial model. Time to the first activity event was analyzed with 
a Cox model. 
Results: We included 159 patients from 12 MS centers in Italy (Age:37.6 years, 
SD:9.3; 73.6% females, median EDSS:3.5, mean disease duration:9.8 years, 
median follow-up 319 days). Pre Alemtuzumab DMTs were: FTY (72 patients), 
NAT (44 patients) other (31 patients), DMT-naive (12 patients). Mean washout 
before Alemtuzumab was 132 days (SD:191). 54 relapses occurred during the 
washout period in 36 patients (ARR=0.83). Mean time to first relapse was 
147±209 days (range 0–1078) from the end of the last DMT. A longer washout 
period was associated with higher ARR during Alemtuzumab (p=0.044) 
independent of previous therapy (p=0.43). ARR in the year pre-discontinuation of 
last treatment was 1.18 (SD: 1.37), and deceased to 0.14 (SD:0.45) during 
Alemtuzumab treatment. The effect was independent of previous treatment 
(p=0.43), that did not impact on time to first event (p=0.85; either relapse/disease 
progression/MRI), as did not washout time (p=0.70), or their interaction (p=0.78). 
Pre-FTY patients showed a pre-Alemtuzumab ARR of 1.25 (SD:1.03) and post-
Alemtuzumab of 0.183 (SD:0.47). Similarly pre-NAT patients showed an ARR of 
0.58 (SD:0.94) and 0.16 (SD:0.53) respectively. 
Conclusions: In this cohort, previous DMTs did not influence the ARR during 
Alemtuzumab, that was constantly well controlled. The longer the washout, the 
higher the ARR, regardless of prior therapy. 
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